PubRank

Mary Young

Author PubWeight™ 134.32‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003 5.81
2 The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004 3.05
3 Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002 2.83
4 Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr 2002 2.30
5 Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis 2002 2.29
6 Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health 2004 2.18
7 Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health 2002 2.15
8 Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007 2.11
9 Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002 2.11
10 Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007 2.10
11 Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med 2004 2.04
12 Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS 2005 2.03
13 Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003 1.95
14 The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 2011 1.94
15 Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS 2004 1.94
16 Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med 2002 1.75
17 Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008 1.71
18 Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis 2011 1.70
19 Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS 2009 1.68
20 Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007 1.66
21 The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012 1.62
22 Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis 2006 1.61
23 Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004 1.58
24 Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatr Soc 2006 1.51
25 Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004 1.50
26 Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study. AIDS 2013 1.43
27 Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt) 2009 1.41
28 Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis 2007 1.37
29 Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr 2012 1.37
30 Association of biomolecular resource facilities survey: service laboratory funding. J Biomol Tech 2009 1.35
31 Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2005 1.31
32 Exosomes derived from HIV-1-infected cells contain trans-activation response element RNA. J Biol Chem 2013 1.31
33 Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS 2009 1.25
34 Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study. J Acquir Immune Defic Syndr 2008 1.22
35 Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation, and naivety. AIDS 2004 1.22
36 Relationship of ethnicity, age, education, and reading level to speed and executive function among HIV+ and HIV- women: the Women's Interagency HIV Study (WIHS) Neurocognitive Substudy. J Clin Exp Neuropsychol 2011 1.20
37 Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 2010 1.19
38 Serum albumin is a powerful predictor of survival among HIV-1-infected women. J Acquir Immune Defic Syndr 2003 1.16
39 Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study. Arch Intern Med 2006 1.13
40 Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006 1.11
41 Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr 2009 1.10
42 Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr 2012 1.08
43 Predictors of reported influenza vaccination in HIV-infected women in the United States, 2006-2007 and 2007-2008 seasons. Prev Med 2010 1.08
44 Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. AIDS 2014 1.06
45 Barriers to, and facilitators for, referral to pulmonary rehabilitation in COPD patients from the perspective of Australian general practitioners: a qualitative study. Prim Care Respir J 2013 1.06
46 Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr 2012 1.03
47 Relative time to pregnancy among HIV-infected and uninfected women in the Women's Interagency HIV Study, 2002-2009. AIDS 2011 1.02
48 Experience of pain among women with advanced HIV disease. AIDS Patient Care STDS 2009 1.02
49 Relation of stavudine discontinuation to anthropometric changes among HIV-infected women. J Acquir Immune Defic Syndr 2007 1.02
50 Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study. Atherosclerosis 2012 1.01
51 Rhodococcus equi pulmonary-central nervous system syndrome: brain abscess in a patient on high-dose steroids--a case report and review of the literature. Diagn Microbiol Infect Dis 2009 1.00
52 Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr 2014 1.00
53 Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study. AIDS 2009 0.99
54 Antiretroviral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDS 2007 0.99
55 Awareness of hepatitis C infection among women with and at risk for HIV. J Gen Intern Med 2007 0.98
56 Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 2013 0.97
57 Lymphoid follicles are generated in high-grade cervical dysplasia and have differing characteristics depending on HIV status. Am J Pathol 2002 0.97
58 Effects of HIV infection and its treatment on self-reported menstrual abnormalities in women. J Womens Health (Larchmt) 2006 0.96
59 Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study. Fertil Steril 2012 0.96
60 Taking it one day at a time: African American women aging with HIV and co-morbidities. AIDS Patient Care STDS 2014 0.95
61 Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. Am J Kidney Dis 2009 0.95
62 Why are some evidence-based care recommendations in chronic obstructive pulmonary disease better implemented than others? Perspectives of medical practitioners. Int J Chron Obstruct Pulmon Dis 2011 0.94
63 Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004 0.94
64 HIV tropism and decreased risk of breast cancer. PLoS One 2010 0.94
65 Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis 2007 0.93
66 Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART. AIDS 2013 0.92
67 Insulin resistance and cognition among HIV-infected and HIV-uninfected adult women: the Women's Interagency HIV Study. AIDS Res Hum Retroviruses 2011 0.92
68 Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS 2013 0.92
69 Correlates of prevalent hypertension in a large cohort of HIV-infected women: Women's Interagency HIV Study. AIDS 2007 0.91
70 Investigation of menopausal stage and symptoms on cognition in human immunodeficiency virus-infected women. Menopause 2014 0.91
71 Cochlear function among HIV-seropositive and HIV-seronegative men and women. Ear Hear 2013 0.90
72 Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy. Clin Infect Dis 2008 0.89
73 Long-term cumulative detection of human papillomavirus among HIV seropositive women. AIDS 2014 0.88
74 Incidence and risk factors for verrucae in women. AIDS 2008 0.88
75 The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women. AIDS 2008 0.87
76 Increased circulating interleukin-7 levels in HIV-1-infected women. J Acquir Immune Defic Syndr 2005 0.87
77 HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients. AIDS 2014 0.86
78 Human immunodeficiency virus (HIV) modulates the associations between insulin resistance and cognition in the current combination antiretroviral therapy (cART) era: a study of the Women's Interagency HIV Study (WIHS). J Neurovirol 2015 0.85
79 Which chronic obstructive pulmonary disease care recommendations have low implementation and why? A pilot study. BMC Res Notes 2012 0.85
80 Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure. J Acquir Immune Defic Syndr 2006 0.85
81 Associations of insulin-like growth factor (IGF)-I and IGF-binding protein-3 with HIV disease progression in women. J Infect Dis 2008 0.85
82 Effects of highly active antiretroviral therapy and its adherence on herpes zoster incidence: a longitudinal cohort study. AIDS Res Ther 2013 0.84
83 Does HIV infection promote early kidney injury in women? Antivir Ther 2013 0.83
84 Incidence of tuberculin skin test conversion among HIV-infected and -uninfected women: results of a 6-year study. J Acquir Immune Defic Syndr 2006 0.83
85 Gonadotropin and sex steroid levels in HIV-infected premenopausal women and their association with subclinical atherosclerosis in HIV-infected and -uninfected women in the women's interagency HIV study (WIHS). J Clin Endocrinol Metab 2013 0.82
86 Highly active antiretroviral therapy reduces urinary albumin excretion in women with HIV infection. J Acquir Immune Defic Syndr 2008 0.82
87 Depressive symptoms are increased in the early perimenopausal stage in ethnically diverse human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Menopause 2012 0.82
88 Trends in contraceptive use among women with human immunodeficiency virus. Obstet Gynecol 2012 0.82
89 T-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHS. J Acquir Immune Defic Syndr 2014 0.82
90 Lower levels of interleukin-12 precede the development of tuberculosis among HIV-infected women. Cytokine 2011 0.81
91 HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study. AIDS 2010 0.81
92 Effect of stress and depression on the frequency of squamous intraepithelial lesions. J Low Genit Tract Dis 2011 0.81
93 Gender-Related Risk Factors Improve Mortality Predictive Ability of VACS Index Among HIV-Infected Women. J Acquir Immune Defic Syndr 2015 0.81
94 Relationship between complementary/alternative treatment use and illicit drug use among a cohort of women with, or at risk for, HIV infection. J Altern Complement Med 2010 0.81
95 Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected women. AIDS Res Hum Retroviruses 2008 0.80
96 Vitamin D and insulin resistance in non-diabetic women's interagency HIV study participants. AIDS Patient Care STDS 2013 0.80
97 Racial/ethnic differences in spontaneous HCV clearance in HIV infected and uninfected women. Dig Dis Sci 2012 0.79
98 Seroincidence of 2009 H1N1 infection in HIV-infected and HIV-uninfected women prior to vaccine availability. AIDS 2011 0.79
99 CCR2 genotype and disease progression in a treated population of HIV type 1-infected women. Clin Infect Dis 2004 0.79
100 Effects of increased ambient temperature on the development of in vitro derived bovine zygotes. Theriogenology 2003 0.78
101 Two cellular proteins that interact with a stem loop in the simian hemorrhagic fever virus 3'(+)NCR RNA. Virus Res 2004 0.78
102 The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients. AIDS Res Ther 2010 0.77
103 Systemic Immune Activation and HIV Shedding in the Female Genital Tract. J Acquir Immune Defic Syndr 2016 0.77
104 Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol gene. J Acquir Immune Defic Syndr 2009 0.76
105 Best-practice care for people with advanced chronic obstructive pulmonary disease: the potential role of a chronic obstructive pulmonary disease care co-ordinator. Aust Health Rev 2013 0.76
106 Systemic cytokine and interferon responsiveness Patterns in HIV and HCV mono and co-infections. J Interferon Cytokine Res 2014 0.76
107 Responses to hepatitis A virus vaccine in HIV-infected women: effect of hormonal contraceptives and HIV disease characteristics. J Acquir Immune Defic Syndr 2012 0.76
108 Life begins at 60: Identifying the social support needs of African American women aging with HIV. J Health Care Poor Underserved 2017 0.75
109 Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection. J Acquir Immune Defic Syndr 2016 0.75
110 Prevalence and Predictors of Hospitalizations Among HIV-Infected and At-Risk HIV-Uninfected Women. J Acquir Immune Defic Syndr 2017 0.75
111 Definition of proteinuria among women with HIV infection. Kidney Int 2004 0.75
112 Risk of breast cancer with CXCR4-using HIV defined by V3 loop sequencing. J Acquir Immune Defic Syndr 2015 0.75
113 Mass spectrometry of murine leukemia virus core proteins. J Virol Methods 2010 0.75
114 Frequency of referral to and attendance at a pulmonary rehabilitation programme amongst patients admitted to a tertiary hospital with chronic obstructive pulmonary disease. Respirology 2013 0.75
115 The experience of patients with advanced chronic obstructive pulmonary disease and advance care-planning: A South Australian perspective. J Law Med 2012 0.75